About Innocoll

Innocoll is a specialty pharmaceutical company committed to improving the status quo and finding answers to unmet needs

XARACOLL® (bupivacaine HCl) Implant

Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020

Latest News

Anthony Galdi Appointed Chief Commercial Officer of Innocoll

ATHLONE, Ireland – Feb. 4, 2021 – Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point...
Read More

Louis Pascarella Appointed Chief Executive Officer of Innocoll

Louis Pascarella has been named the company’s Chief Executive Officer and a member of Innocoll’s Board of Directors. Pascarella, who will retain his current role of President, succeeds Rich Fante, who is stepping down after a successful tenure as CEO and has agreed to serve as an adviser to Innocoll’s Board for at least the next year to ensure a smooth transition.
Read More

Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI) implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

First-in-class, fully bioresorbable, collagen implant delivers postsurgical pain relief directly to the surgical site ATHLONE, Ireland, Oct. 29, 2020 /PRNewswire/ -- Innocoll Holdings Limited,...
Read More